quarta-feira, 7 de outubro de 2026
PesquisarExplore
Via News Knowledge File

Uber Technologies

organization80% conf.·synced Aug 13, 2026

Technology company backing Aurora Innovation

57
sourced metrics
320
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Ai Cost Per Engineer
2000USD_per_month
Aug 6, 2026source
Trading Volume
46.2million_shares
Aug 5, 2026source
Stock Price
68.18USD
Aug 5, 2026source
Market Share
11.5percent
Jul 15, 2026source
Lucid Nuro Vehicle Commitment
35000vehicles
Jun 30, 2026source
Forward Pe Ratio
24ratio
Jun 30, 2026source
Rivian Vehicle Commitment
50000vehicles
Jun 30, 2026source
Daily Trips
40millions
Jun 30, 2026source
Autonomous Vehicle Commitment
10USD
Jun 30, 2026source
Autonomous Partners Count
30count
Jun 30, 2026source
Trips Completed
75billion_trips
Jun 17, 2026source
Founding Year
2010year
Jun 17, 2026source
Trip Volume
3.64billions
May 1, 2026source
Ebitda Growth
33percent
May 1, 2026source
Trip Volume Growth
20percent
May 1, 2026source
Gross Bookings Growth
25percent
May 1, 2026source
Gross Bookings
53.7USD
May 1, 2026source
Ebitda
2.5USD
May 1, 2026source

Stated objectives

Launch commercial autonomous robotaxi service in Bay Area

source
by 2026-12-01 00:00:00stated

Grow Gross Bookings in the mid-teens percentage range

source
target: mid-teens percent stated

Grow EBITDA in the high-30s to 40% range

source
target: 35-40 percent stated

Expand free cash flow margins toward 20%

source
target: 20 percent by 2027-01-01 00:00:00stated

Increase market penetration beyond 15% of adult population in top 10 markets

source
stated

Expand suburban market presence where growth is 1.5 to 3 times faster than metro areas

source
stated

Converge reported operating income closer to Adjusted EBITDA by reducing one-off costs

source
stated

Expand advertising business beyond initial 2% penetration cap to become one of Uber's most important profit drivers

source
stated

Expand into grocery, retail, convenience items, and other everyday goods delivery beyond restaurant food

source
stated

Extend business model into suburban and smaller markets where penetration remains low

source
stated

Relationship graph · 320 connections

Invested in
53
Covered by
43
Supplies to
42
Competes with
36
Customer of
30
Partners with
19
Employs
18
Partnered with
12
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com